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Nearly 40 years ago, DNA was sequenced for the first
time. Since then, DNA sequencing has undergone
continuous development, passing through three
generations of sequencing technology. We are now
entering the beginning of a new phase of genomic
analysis in which massively parallel sequencing is
performed directly in the cell. Two methods have
recently been described for in situ RNA sequencing,
one targeted and one untargeted, that rely on ligation
chemistry. This fourth generation of sequencing
technology opens up prospects for transcriptomic
analysis, biomarker validation, diagnosis and patient
stratification for cancer treatment.ial is generally fragmented, clonally amplified and loadedThe first three generations
Nucleic acid sequencing has undergone rapid and im-
pressive development. The effect of ceaseless techno-
logical improvement is illustrated by the reduced speed
and cost of recent sequencing approaches and the quan-
tity of data being produced. It is also reflected in the
way medicine is changing in the so-called ‘genomic era’,
in which sequencing each person’s genome is becoming
a real possibility for routine clinical practice. A very re-
cent development is in situ sequencing to read nucleic
acid sequences within tissues and cells [1,2]. With
optimization, this approach is likely to be extremely use-
ful in the clinic for diagnosis and personalized medicine.
Such fourth-generation technology builds upon the earl-
ier ground-breaking methods for DNA sequencing.
The first methods used to sequence DNA were de-
scribed in the 1970s. The most prominent were chemical
sequencing by Maxam and Gilbert [3] and the chain ter-
mination method by Sanger and colleagues [4]. Both
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org/publicdomain/zero/1.0/) applies to the dataelectrophoresis of four pools of reactions to reconstruct
the DNA sequence. The first turning point in DNA se-
quencing came when Leroy Hood and his laboratory, in
the mid-1980s, replaced radioactive labeling with fluor-
escent dyes and automated the Sanger method [5]. This
improvement formed the basis for the development and
commercialization of capillary electrophoresis sequen-
cing machines, which allowed the assembly of the first
draft complete human genome ever sequenced, in 2001.
The next turning point in DNA analysis was the intro-
duction of second-generation sequencing machines, the
so called next-generation sequencing (NGS) technolo-
gies, in 2005 [6]. Researchers moved from chain termin-
ation methods and electrophoresis separation to
sequencing platforms in which the DNA starting mater-
on sophisticated microchips or wells for sequencing.
The Sanger method was replaced by newly developed
chemistries that allow massively parallel sequencing of
the human genome or transcriptome in hours to days. A
third generation of sequencing methods of single nucleic
acid molecules has also been introduced and promises
longer, easier to map sequencing reads and lower costs.
However, these true single-molecule sequencing ap-
proaches have not yet become robust enough for broad
use.Fourth-generation sequencing
The recently described new (fourth) generation in situ
sequencing method exploits second-generation NGS
chemistry to read nucleic acid composition directly in
fixed cells and tissues. Last year, in situ sequencing of
mRNA was demonstrated for the first time. We used a
targeted method to sequence short nucleotide sequences
in breast cancer tissue sections [2]. We first generated
cDNA in situ and then we used padlock probes, which
are approximately 70-base-long oligonucleotides, to encir-
cle a short target sequence of four to six bases (Figure 1).
The gap left between the end arms of the padlock probe
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Figure 1 Molecular steps to generate sequencing substrate in targeted and non-targeted in situ sequencing. (a) In the targeted
approach, a specific or random primer is used to retrotranscribe mRNA (gray) (i), the synthesized cDNA is made single stranded and a padlock
probe is hybridized to complementary target sequences on the cDNA molecule (ii, iii), leaving a short gap between the probe arms (in red).
Polymerization gap filling and DNA ligation are used to circularize the padlock probe (iv), which can be then replicated via target-primed rolling
circle amplification (v). (b) In non-targeted in situ sequencing, the cDNA is synthesized by random primers containing a sequencing adaptor (vi).
RNA is then digested and single-stranded cDNA molecules are self-circularized (ii, iii). An external primer is then hybridized and used to prime the
rolling circle amplification (RCA) reaction (ix, x). In both the approaches, the sequencing substrate consists of a rolling circle product containing a
clonally amplified region of DNA (colored in red or green), which is sequenced in situ by sequencing using ligation chemistries.
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ing circle amplification (RCA). We then used sequencing
by ligation chemistry developed by Drmanac and col-
leagues [7] to read the target region thus cloned on the
rolling circle product.
Recent work by Lee, Daugharthy and colleagues repre-
sents a step further in the development of fourth-
generation technology [2]. The authors describe a novel
strategy to generate amplicons in a non-targeted fashion
in which random hexamers tagged with a sequencing
adaptor are used to reverse transcribe RNA molecules in
situ. The newly synthesized cDNA self-circularizes and
is amplified via RCA (Figure 1). The amplicons are cova-
lently linked to cellular proteins and can be generated in
many different cell types, tissue sections and whole-
mount embryos. Target mRNA molecules can beunambiguously identified thanks to the impressive read
length of 27 nucleotides obtained by implementing se-
quencing by oligonucleotide ligation and detection
(SOLiD) chemistry in the protocol [8].
The RNA-rich cellular environment poses a difficult
challenge to achieving a readable density of sequencing
library in situ. In fact, a physical limitation exists to the
number of spots distinguishable at the optical resolution
used by the in situ sequencing methods described so far.
In our approach, the theoretical limitation is about 100
reads per cell and we propose strategies to go beyond
this limit [2]. Church’s group overcome this limitation
by partition sequencing, in which randomly mismatched
sequencing primers are used to decrease read density,
imaging only a pool of the total reads every cycle [1].
They achieved an average density of 400 reads per cell,
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the authors show simultaneous expression of thousands
of genes uniquely mapping to mRNA but also to rRNA,
non-coding RNA and anti-sense RNA in fibroblasts and
induced pluripotent stem cells. They further demon-
strate the feasibility of their method to identify fibroblast
subpopulations in a wound-healing model by detecting
thousands of differentially expressed genes.
In situ sequencing for research and diagnostics
In situ sequencing differs from previous sequencing gen-
erations in two respects, both of which are relevant for
its use in research and diagnostics. First, the spatial dis-
tribution of the sequencing reads over the sample can be
seen, adding an important level of information. We
demonstrated in our article how this information can be
used to visualize tissue heterogeneity based on a number
of known molecular markers.
Lee and colleagues showed that subcellular resolution
can be achieved with their method, an interesting feature
that would allow the study of regulatory elements such
as non-coding RNA species in complex populations of
cells, for example, in brain tissue. A second difference is
the throughput in terms of the number of cells it is pos-
sible to simultaneously analyze. Single-cell RNA sequen-
cing methods have been developed to work robustly
with just a few picograms of starting material, and there
has been an increase in the rate of cell sequencing as
well as a decrease in cost [9]. However, tissue material
routinely used in diagnostics is composed of hundreds
of thousands of cells. To dissociate and sequence single
cells is technically and computationally challenging and
the huge amount of information returned may not be
cost effective. By sequencing RNA molecules in situ in-
stead, information can be obtained by thousands of cells
at the same time while maintaining single-cell or even
subcellular resolution.
Although in its infancy, we foresee the use of in situ
sequencing as a complementary tool to filter clinically
relevant information from the massive amounts of data
produced by traditional NGS methods, and to translate
it into molecular diagnostic applications. It is likely that
biomarker discovery and validation will still be done by
performing deep sequencing on extracted nucleic acids.
A targeted in situ sequencing approach may be useful
instead to screen for validated biomarkers directly on
routine samples while a non-targeted approach may be
used to molecularly profile samples for patient stratifica-
tion or molecular classification of disease. For example,
at least two features make in situ sequencing interesting
for cancer diagnostic applications. First, this method
achieves single-nucleotide resolution, enabling both de-
tection of clinically relevant point mutations, allelic vari-
ants and splice variants, and tissue expression profiling.Second, adding molecular information to classic mor-
phological microscopic analysis allows digital and quan-
tifiable representation of the heterogeneity of the
sample, which may be important, for instance, for tumor
grading and classification. It will also be useful for study-
ing local effects, such as the contribution of the tumor
microenvironment to cancer growth or tumor clonal
evolution.
The two described approaches for in situ RNA se-
quencing promise exciting future prospects for research
and molecular diagnostics, but further development is
needed. Time, cost and the amount of manual procedure
needed to perform a sequencing run are far from suit-
able for any clinical laboratory. A lesson learnt from
NGS technologies is that, if the techniques described
here hold the potential that we foresee, all these limiting
factors will diminish in a few years. The implementation
of in situ sequencing in one of the existing NGS platforms
would speed up the development of these methods,
enabling them to become a fundamental tool for per-
sonalized medicine.
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